Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2003

View Archived Issues

Valentis and Schering sign multiproduct agreement for gene-based therapeutic products

Campath enters phase I/II trial in NHL

Milnacipran demonstrates analgesic efficacy in animal model of FMS

G17DT granted orphan drug status in Australia for gastric and pancreatic cancers

Cephalon files sNDA for Provigil

Olux approved for treatment of psoriasis

Bicifadine enters phase III for postsurgical dental pain

Oxigene begins phase II trial of CA4P in thyroid cancer

CeNeS outlicenses CEE-03-310 to Swiss biopharmaceutical company

Joint development agreement signed by Beaufour Ipsen and Roche for new anticancer drugs

Collaboration to develop drugs for atrial fibrillation renewed by ICAgen and BMS

Novartis files supplemental NDA for Starlix

Genelabs submits MAA for lupus drug in Europe

Relpax granted FDA approval

SuperGen submits first module of rolling NDA for Orathecin

Genentech and Xoma submit BLA for FDA approval of Raptiva

Foradil Certihaler filed for approval in the U.S.

Beneficial long-term effects of arzoxifene on bone and lipids in ovariectomized rats

Inhibition of tight junction function as a novel approach to breast cancer

Highly potent, orally available human glucagon receptor antagonist with antihyperglycemic activity

Potential antileukemia agents selected from series of arsonic acids

Meiji Seika identifies potent, selective and orally available 5-HT7 receptor antagonist

Small-molecule GFRalpha-1 agonist mimics effects of GDNF in neuroblastoma cells

New modulators of glucose and lipid levels designed by Dr. Reddy's researchers

Humira approved by FDA for RA

Azido-based photosensitizers covered by Mallinckrodt patent

Adenine nucleotide translocator-binding compounds and their use reported by MitoKor

Novel prodrugs of FBPase inhibitors prepared and tested at Metabasis Therapeutics

Tularik presents new CXCR3 antagonists with utility in restenosis and other disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...